Teduglutide

Overview

The intestinal counterpart to the GLP-1 drugs. Where GLP-1 suppresses appetite, GLP-2 makes the remaining bowel physically grow — taller villi, deeper crypts, more absorptive surface. For patients living on intravenous nutrition, that is the difference between a pump every night and a life.

How it works

Agonises GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, triggering mucosal growth: increased villus height and crypt depth, slowed gastric emptying and transit, and increased intestinal blood flow. A single alanine-to-glycine substitution blocks DPP-4 degradation, extending half-life from minutes to hours.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• Phase 3 trials with an objective, hard-to-game endpoint: litres of intravenous nutrition avoided.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Reduces parenteral nutrition dependence Strong evidence

  A substantial proportion of patients achieved clinically meaningful reductions in weekly parenteral support volume, and some achieved complete independence from it.

• Genuine mucosal growth Strong evidence

  Biopsy-confirmed increases in villus height and crypt depth — structural change, not just symptom improvement.

• Reduces infusion days per week Strong evidence

  Fewer nights tethered to a pump, with direct quality-of-life consequences.

• Durable with continued therapy Moderate evidence

  Extension studies show benefit maintained over years of treatment.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Colorectal cancer surveillance required Serious

  A drug whose entire mechanism is intestinal growth carries a theoretical neoplasia risk. Colonoscopy is required before starting and periodically thereafter, with polyp removal.

• Bowel obstruction Serious

  Mucosal growth can narrow an already compromised lumen; stoma stenosis and obstruction are recognised complications.

• Biliary and pancreatic disease Serious

  Cholecystitis, cholangitis and pancreatitis are labelled risks requiring periodic laboratory assessment.

• Fluid overload Moderate evidence

  Improved absorption can cause fluid overload if parenteral support is not reduced in step — congestive heart failure has been reported.

• Benefit reverses on stopping Moderate evidence

  The mucosal changes regress after discontinuation; it is indefinite therapy.

• Very high cost Minor

  Among the more expensive chronic therapies in gastroenterology.

Who should avoid it

• Active gastrointestinal malignancy
• Active malignancy elsewhere within the last 5 years (relative)
• Known colorectal polyps not yet removed
• Pregnancy (insufficient data)

If used under medical supervision, monitor

• Colonoscopy before initiation, at 1 year, then every 5 years
• Bilirubin, alkaline phosphatase, lipase and amylase every 6 months
• Fluid balance and parenteral support volume
• Stoma assessment where present

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• Oral medications — increased absorption may require dose reduction of drugs with narrow therapeutic windows
• Parenteral nutrition — must be actively reduced as absorption improves

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Prescription drug, typically prescribed through specialist intestinal failure centres.

Infographic

Teduglutide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Teduglutide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Gut & Gastrointestinal